NCT04990778 2022-03-10
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT03072043 2022-01-24
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02999893 2021-12-13
APROC
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Terminated
NCT03588078 2020-01-30
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
Groupe Francophone des Myelodysplasies
Phase 1/2 Unknown